India Court Orders Precedent-Setting Use Of CL For Bayer’s Nexavar
This article was originally published in PharmAsia News
Executive Summary
India’s High Court has cleared the nation’s first compulsory license, allowing Natco Pharma to market a generic of Bayer’s Nexavar (sorefinib) cancer drug, despite Bayer’s current patent.